Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

USE OF ORALLY ADMINISTERED LIVE ATTENUATED POLIOVIRUSES AS A VACCINE IN A COMMUNITY SETTING

USE OF ORALLY ADMINISTERED LIVE ATTENUATED POLIOVIRUSES AS A VACCINE IN A COMMUNITY SETTING Attenuated strains of the three types of poliovirus were used in a study of 550 volunteer subjects. Subjects in group A received a placebo during the first 76 days of the study while those in group B received the polioviruses by mouth; during the remaining days (78th to 139th) group A received the viruses and group 8 the placebo. No particular type of symptom or reaction marked the entrance of the virus into the body. The children, and to a lesser extent the adults, receiving the virus manifested a generally increased titer of neutralizing antibody. The results for children and adults receiving the placebo were quite different. The positive responses occurred despite the fact that a substantial number of the participants had previously received Salk vaccine. Although the effectiveness of vaccination needs to be demonstrated finally in encounters with the disease itself, this study yielded strong evidence of the effectiveness as well as the safety of the living attenuated poliovirus used. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

USE OF ORALLY ADMINISTERED LIVE ATTENUATED POLIOVIRUSES AS A VACCINE IN A COMMUNITY SETTING

Loading next page...
 
/lp/american-medical-association/use-of-orally-administered-live-attenuated-polioviruses-as-a-vaccine-XHMpRbXksi
Publisher
American Medical Association
Copyright
Copyright © 1959 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1959.03010080001001
Publisher site
See Article on Publisher Site

Abstract

Attenuated strains of the three types of poliovirus were used in a study of 550 volunteer subjects. Subjects in group A received a placebo during the first 76 days of the study while those in group B received the polioviruses by mouth; during the remaining days (78th to 139th) group A received the viruses and group 8 the placebo. No particular type of symptom or reaction marked the entrance of the virus into the body. The children, and to a lesser extent the adults, receiving the virus manifested a generally increased titer of neutralizing antibody. The results for children and adults receiving the placebo were quite different. The positive responses occurred despite the fact that a substantial number of the participants had previously received Salk vaccine. Although the effectiveness of vaccination needs to be demonstrated finally in encounters with the disease itself, this study yielded strong evidence of the effectiveness as well as the safety of the living attenuated poliovirus used.

Journal

JAMAAmerican Medical Association

Published: Jun 20, 1959

There are no references for this article.